August Bioservices, LLC

August Bioservices, LLC, based in Nashville, US, offers comprehensive contract development and manufacturing organization (CDMO) services, specializing in drug research and development solutions, including cGMP laboratory services and sterile fill/finish manufacturing. August Bioservices is engaged in contract development and manufacturing for the pharmaceutical sector, having been founded in 2017 in Nashville, US. The company has raised a total of USD 65. 00 mn in funding through 3 deals, with the most recent being a Series B round in December 2022 led by Oak HC/FT Partners, which participated alongside Polaris Partners.

The company is led by CEO Jenn Adams, who has a background in managing drug development initiatives. August Bioservices specializes in comprehensive contract development and manufacturing organization (CDMO) services, providing end-to-end solutions for drug research and development, as well as cGMP laboratory services and sterile fill/finish manufacturing. The company addresses specific needs such as sterile injectables and complex formulations, serving a diverse clientele including biopharmaceutical firms and research institutions across North America, Europe, and Asia. Operating on a B2B model, August Bioservices generates revenue through project-based agreements with pharmaceutical and biotechnology companies.

Clients engage with the company for specific stages of drug formulation and production, with fees based on the complexity and scale of services, particularly in sterile fill/finish processes and complex formulation development. In December 2022, August Bioservices, LLC raised USD 65 mn in Series B funding, which will be utilized to enhance operations and expand production capabilities. The company aims to develop new products and extend its services into additional markets, although specific release dates and regions are yet to be detailed.